Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors
Authors:
- Hongyu ZhaoHZHongyu Zhao
- Michael D. SerbyMSMichael D. Serby
- Harriet T. SmithHSHarriet T. Smith
- Ning CaoNCNing Cao
- Tom S. SuharTSTom S. Suhar
- Teresa K. SurowyTSTeresa K. Surowy
- Heidi S. CampHCHeidi S. Camp
- Christine A. CollinsCCChristine A. Collins
- Hing L. ShamHSHing L. Sham
- Gang LiuGLGang Liu
- 1 June 2007
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (12) , 3388-3391
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspectiveDrug Discovery Today, 2007
- Regulation of stearoyl-CoA desaturases and role in metabolismProgress in Lipid Research, 2004
- The Role of Stearoyl-CoA Desaturase in Body Weight RegulationTrends in Cardiovascular Medicine, 2004
- Stearoyl-CoA Desaturase-1 and the Metabolic SyndromeCurrent Drug Target - Immune, Endocrine & Metabolic Disorders, 2003
- Hit and lead generation: beyond high-throughput screeningNature Reviews Drug Discovery, 2003
- Role of stearoyl-coenzyme A desaturase in lipid metabolismProstaglandins, Leukotrienes and Essential Fatty Acids, 2003
- Loss of stearoyl–CoA desaturase-1 function protects mice against adiposityProceedings of the National Academy of Sciences, 2002
- Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouseNature Genetics, 1999
- “Scaffold-Hopping” by Topological Pharmacophore Search: A Contribution to Virtual ScreeningAngewandte Chemie International Edition, 1999
- The regulation of stearoyl-CoA desaturase (SCD)Progress in Lipid Research, 1995